# Kailera Therapeutics, Inc. Common Stock (KLRA)

> Kailera Therapeutics, Inc. Common Stock (KLRA) trades at $11.62 (-4.75%) as of 7:30:03 PM EST on Nov 18, 2026, -8.53% over the past month. Market cap is $1.53B, with 7.8 days to cover in short interest.

Canonical: https://massive.com/quote/klra
Data as of: 2026-11-19T00:30:03.159Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$11.62** -0.58 (-4.75%)
As of 7:30:03 PM EST on Nov 18, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Kailera Therapeutics, Inc. Common Stock (KLRA) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -3.36% |
| 1W | -18.01% |
| 1M | -8.53% |
| YTD | -54.65% |
| 1Y | -54.65% |
| 52-wk range | $9.76 – $28.23 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for KLRA: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $11.79 – $12.51 |
| Open | $12.17 |
| Prev close | $12.20 |
| Volume | 418.8K |
| Market cap | $1.53B |
| Shares out | 129.85M |

## Valuation and profitability ratios

Valuation and profitability ratios for Kailera Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 1.48 |
| P/FCF | — |
| ROE | -31.6% |
| ROA | -30.1% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 18, 2026

## Insider trading

[Kailera Therapeutics, Inc. Common Stock (KLRA) insider trading](https://massive.com/quote/klra/insider-trading.md): open-market Form 4 buys and sells by Kailera Therapeutics, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Kailera Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 4, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 4, 2026, Kailera Therapeutics, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended September 30, 2026.”
- Apr 20, 2026 · Bylaw amendment
  “On April 20, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company became effective. The Amended and Restated Bylaws amended and restated the Company's prior bylaws in their entirety to, among other things: (i) establish procedures relating to the presentation of stockholder proposals at stockholder meetings; (ii) establish procedures relating to the nomination of directors; and (iii) conform to the amended provisions of the Restated Certificate.”

## KLRA short interest

How heavily KLRA is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 7.8 |
| Short interest | 8.16M |
| Avg volume | 1.04M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## KLRA news

The latest news and headlines about Kailera Therapeutics, Inc. Common Stock (KLRA).

- [3 Under-the-Radar Stocks to Buy and Hold for a Decade](https://www.fool.com/investing/2026/06/16/3-under-the-radar-stocks-to-buy-and-hold-for-a-dec/?source=iedfolrf0000001) · The Motley Fool · Jun 16, 2026 · positive sentiment
- [Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026](https://www.globenewswire.com/news-release/2026/06/05/3307661/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Present-Ribupatide-Clinical-Data-at-ADA-2026.html) · GlobeNewswire Inc. · Jun 5, 2026 · positive sentiment
- [Is Kailera Therapeutics a Buy After Its Sizzling IPO?](https://www.fool.com/investing/2026/05/16/is-kailera-therapeutics-a-buy-after-its-sizzling/?source=iedfolrf0000001) · The Motley Fool · May 16, 2026 · neutral sentiment
- [Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy](https://www.benzinga.com/Opinion/26/04/52006951/kailera-therapeutics-strong-ipo-validates-newco-strategy?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Apr 23, 2026 · positive sentiment
- [Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares](https://www.benzinga.com/pressreleases/26/04/g51925881/kailera-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-p?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Apr 20, 2026 · positive sentiment

## About Kailera Therapeutics, Inc. Common Stock

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| IPO | $16.00 on Apr 17, 2026 |

[Kailera Therapeutics IPO page](https://massive.com/quote/klra/ipo.md)

[Company website](https://www.kailera.com)

## FAQ

### What is the Kailera Therapeutics, Inc. Common Stock (KLRA) stock price today?

Kailera Therapeutics, Inc. Common Stock (KLRA) is trading at $11.62 (-4.75% on the day) as of 7:30:03 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Kailera Therapeutics, Inc. Common Stock?

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity.

### What is the short interest in KLRA?

As of Oct 30, 2026, KLRA has 8.16M shares short and 7.8 days to cover.

### What exchange is KLRA listed on?

Kailera Therapeutics, Inc. Common Stock (KLRA) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time KLRA quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=KLRA`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Kailera Therapeutics, Inc. Common Stock (KLRA) insider trading](https://massive.com/quote/klra/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
